News and Media

On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with […]

“Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, […]

Tchaikapharma has expanded its portfolio with another product, namely Fluidoro 10 mg film-coated tablets (with active ingredient prasugrel). It belongs to a group of drugs called platelet antiaggregants – it inhibits the accumulation of platelets and thus reduces the risk of blood clots.   Fluidoro, given concomitantly with acetylsalicylic acid (ASA), is indicated for the […]

Tchaikapharma’s product portfolio was presented at the 6th congress of the Society of Cardiologists of Kosovo under the auspices of the European Society of Cardiology. Тhe company’s top products Tamaira, Co-Telsart, Amariton and Rosta were of particular interest as the preferred choice of the cardiologists in the country. This is one of the reasons why […]

  The pandemic has caused problems in the forefront of predictability and access to medicines in the country. It was difficult to supply the basic (active) substances for pharmaceutical production, and a slight increase in the production of drugs.   In this context, even before the first global lockdown, the team of Tchaikapharma has prepared […]